| Buprenorphine induces ceiling in respiratory depression but not in analgesia A Dahan, A Yassen, R Romberg, E Sarton, L Teppema, E Olofsen, ... BJA: British Journal of Anaesthesia 96 (5), 627-632, 2006 | 426 | 2006 |
| Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats A Dahan, A Yassen, H Bijl, R Romberg, E Sarton, L Teppema, E Olofsen, ... British journal of anaesthesia 94 (6), 825-834, 2005 | 350 | 2005 |
| Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research M Danhof, ECM De Lange, OE Della Pasqua, BA Ploeger, RA Voskuyl Trends in pharmacological sciences 29 (4), 186-191, 2008 | 322 | 2008 |
| Therapeutic drug monitoring in saliva M Danhof, DD Breimer Clinical pharmacokinetics 3 (1), 39-57, 1978 | 314 | 1978 |
| Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis M Danhof, J de Jongh, ECM De Lange, O Della Pasqua, BA Ploeger, ... Annu. Rev. Pharmacol. Toxicol. 47, 357-400, 2007 | 290 | 2007 |
| Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood–brain barrier ECM de Lange, M Danhof, AG de Boer, DD Breimer Brain research reviews 25 (1), 27-49, 1997 | 274 | 1997 |
| The role of population PK–PD modelling in paediatric clinical research RFW De Cock, C Piana, EHJ Krekels, M Danhof, K Allegaert, CAJ Knibbe European journal of clinical pharmacology 67, 5-16, 2011 | 271 | 2011 |
| Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and … ECM de Lange, M Danhof Clinical pharmacokinetics 41, 691-703, 2002 | 265 | 2002 |
| Markers of disease severity in chronic obstructive pulmonary disease LG Franciosi, CP Page, BR Celli, M Cazzola, MJ Walker, M Danhof, ... Pulmonary pharmacology & therapeutics 19 (3), 189-199, 2006 | 250 | 2006 |
| Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans CH Kleinbloesem, PV Brummelen, M Danhof, H Faber, J Urquhart, ... Clinical Pharmacology & Therapeutics 41 (1), 26-30, 1987 | 248 | 1987 |
| Pharmacokinetic‐pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α‐hydroxymidazolam in healthy volunteers JW Mandona, B Tuk, AL van Steveninck, DD Breimer, AF Cohen, ... Clinical Pharmacology & Therapeutics 51 (6), 715-728, 1992 | 239 | 1992 |
| Extensions to the visual predictive check to facilitate model performance evaluation TM Post, JI Freijer, BA Ploeger, M Danhof Journal of pharmacokinetics and pharmacodynamics 35, 185-202, 2008 | 230 | 2008 |
| Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man CH Kleinbloesem, P Van Brummelen, H Faber, M Danhof, ... Biochemical pharmacology 33 (22), 3721-3724, 1984 | 220 | 1984 |
| Mechanism-based pharmacokinetic–pharmacodynamic modeling—a new classification of biomarkers M Danhof, G Alvan, SG Dahl, J Kuhlmann, G Paintaud Pharmaceutical research 22, 1432-1437, 2005 | 208 | 2005 |
| Clinical pharmacokinetics of pioglitazone DA Eckland, M Danhof Experimental and clinical endocrinology & diabetes 108 (Sup. 2), 234-242, 2000 | 191 | 2000 |
| Characterization of an" in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. JB Van Bree, AG De Boer, M Danhof, LA Ginsel, DD Breimer Journal of Pharmacology and Experimental Therapeutics 247 (3), 1233-1239, 1988 | 191 | 1988 |
| Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man M Danhof, E de Groot-van der Vis, DD Breimer Pharmacology 18 (4), 210-223, 1979 | 187 | 1979 |
| Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs JW Mandema, M Danhof Clinical pharmacokinetics 23, 191-215, 1992 | 185 | 1992 |
| What is the right dose for children? M Cella, C Knibbe, M Danhof, O Della Pasqua British journal of clinical pharmacology 70 (4), 597, 2010 | 181 | 2010 |
| A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus W Winter, J DeJongh, T Post, B Ploeger, R Urquhart, I Moules, D Eckland, ... Journal of pharmacokinetics and pharmacodynamics 33, 313-343, 2006 | 177 | 2006 |
